Gilead Sciences stock costs EUR 130.59, volume 2,080,114 shares

Published on 10/08/2026 at 20:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Truist set a USD 158.00 target on October 7, 2026. Gilead Sciences stock costs EUR 130.59 on October 8, 2026 versus EUR 131.16.

Key points in brief

Gilead Sciences stock was at EUR 130.59 at Lang & Schwarz on October 8, 2026 at 8:06 p.m. CEST, minus 0.43 percent versus EUR 131.16.
Trading volume was 2,080,114 shares against an average of 6,007,092 shares on October 8, 2026.
Truist raised its Gilead target from USD 150.00 to USD 158.00 on October 7, 2026.

Flatlay mit Aktienzertifikat ISIN US3755581036 Gilead Sciences Labormaterialien auf Marmor — Gilead Sciences Flatlay ISIN US3755581036 Aktienzertifikat ISIN-Karte Ampullen Molekülmodell Stethoskop weißer Marmor, Illustration mit AI erstellt.

Gilead Sciences stock was trading at EUR 130.59 at Lang & Schwarz on October 8, 2026 at 8:06 p.m. CEST, down 0.43 percent versus the EUR 131.16 prior close on October 7, 2026. The quote was in after-hours trading from a German investor perspective.

Volume trails the average

Trading volume stood at 2,080,114 shares on October 8, 2026, compared with an average volume of 6,007,092 shares. That places the session at 34.63 percent of the average, a concrete measure of participation alongside the 0.43 percent decline.

The primary-market quote was last at USD 146.54 on Nasdaq on October 8, 2026 at 2:11 p.m. ET, down 0.21 percent on the same exchange. The separate US-dollar quotation is not combined with the euro move.

Range leaves room above

Gilead Sciences traded between a 52-week low of USD 114.02 and a 52-week high of USD 157.29 as of October 8, 2026. The Nasdaq quote of USD 146.54 was 6.83 percent below that high, while the Lang & Schwarz price provides the euro-based view for investors in Germany.

Market capitalization stood at USD 181.7 billion on October 8, 2026, and the reported price-to-earnings ratio was minus 54.89. The company operates in healthcare and the drug manufacturers general industry, with HIV, oncology and inflammation medicines forming the core of its portfolio.

Target revisions remain mixed

MarketBeat reported on October 8, 2026 that Royal Bank of Canada raised its target from USD 123.00 to USD 126.00 while maintaining a sector perform rating. The revision is below the Nasdaq quote of USD 146.54, making it a more cautious counterpoint to the broader analyst range.

MarketBeat also reported on October 7, 2026 that Truist raised its target from USD 150.00 to USD 158.00 and kept a buy rating. The USD 158.00 target stood 7.82 percent above the Nasdaq quote of USD 146.54 on October 8, 2026.

Comparison with peers

Gilead Sciences: minus 0.43 percent, P/E minus 54.89, market capitalization USD 181.7 billion
Vertex Pharmaceuticals (Nasdaq, USD): minus 0.12 percent, P/E 29.41, market capitalization USD 128.2 billion
Regeneron Pharmaceuticals (Nasdaq, USD): minus 0.61 percent, P/E 18.23, market capitalization USD 76.0 billion

Next report date

MarketBeat lists October 29, 2026 as Gilead Sciences' next quarterly reporting date, after the market close. The date gives the current price report a defined calendar reference without changing the market data.

After-hours price stays below the close

At Lang & Schwarz, Gilead Sciences was trading at EUR 130.59 on October 8, 2026 at 8:06 p.m. CEST, minus 0.43 percent versus the EUR 131.16 prior close dated October 7, 2026. real-time quote of Gilead Sciences stock.